Walter and Eliza Hall Institute of Medical Researchĭevelopment of nuclear mRNA targeting therapeutics to treat cancer RNA delivery of therapeutic gene editing to blood stem cellsĬancer Epigenetics Laboratory, Trinity College DublinĪ modular platform for the development of mRNA-based epigenetic drugs: a pilot. Victoria University of Wellington, New ZealandĪ mRNA vaccine for preventing liver-stage malaria MRNA-encoded nanobody therapy against COVID-19 The use of mRNA therapy for blood cell cancers St Vincent's Institute of Medical Research Using lipid nanoparticles to deliver novel combination RNA therapeutics for pulmonary bacterial infectionsīuilding predictive power to fast-track the evaluation and prioritisation of nanocarriers for therapeutic RNA delivery in brain cancerĭevelopment of an mRNA vaccine for a human bacterial pathogen Porphyromonas gingivalis involved in Periodontitis and Alzheimer's Disease. The Peter Doherty Institute for Infection and Immunity The Walter and Eliza Hall Institute of Medical Research Round 2 recipients were announced in June 2023, with $2,747,426 of funding shared across 16 projects. Grants Successful recipient mRNA Victoria Research Acceleration Fund Round 2 Victoria is also home to the Australian Government’s Australian Centre for Disease Preparedness operated by the CSIRO, and the Geelong Centre for Emerging Infectious Diseases. In May 2021, Victoria committed $400 million to establish the Australian Institute for Infectious Diseases, to be located beside the Doherty Institute, the first place in the world outside of China to decipher the genetic code for COVID-19. Victoria leads Australia in clinical trial capability, with the greatest number of trials underway of any state. Victoria’s life sciences professionals number more than 100,000 with the majority of the nation’s pharmaceutical life sciences professionals living in Victoria. Nearly 60 per cent of Australia’s pharmaceutical exports are from Victoria. 70 per cent of the top 25 Australian medtech and pharma companies are based in Victoria. Victoria is home to CSL, the second largest influenza vaccine manufacturer in the world. Dr Minna-Liisa Änkö - Head, Functional RNAomics laboratory, Hudson Institute of Medical Research.Professor Ricky Johnstone - Head, Gene Regulation Laboratory, Peter MacCallum Cancer Centre.Professor Andrew Steer - Director, Infection and Immunity, Murdoch Children’s Research Institute.Professor John Carroll - Director, Monash Biomedicine Discovery Institute.Professor Terry Nolan - Head, Vaccine and Immunisation Research Group, Doherty Institute at University of Melbourne, and MCRI.Professor Doug Hilton - Director, Walter and Eliza Hall Institute of Medical Research.Professor Brendan Crabb - Director, Burnet Institute.Professor William Charman - Sir John Monash Distinguished Professor, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University.Dr Barney Graham - Deputy Director, Vaccine Research Center, US National Institutes of Health.Professor Sharon Lewin - Director, Doherty Institute.Dr Amanda Caples - Victoria’s Lead Scientist and Chair of the Group.The SAG works in consultation with mRNA Victoria, supporting the development of the mRNA ecosystem and research in Victoria. MRNA Victoria is advised by a Scientific Advisory Group (SAG) made up of world-leading experts from the medical research sector. mRNA Victoria’s Scientific Advisory Group Its role is to identify key capabilities, gaps and opportunities and to lead the Victorian Government’s engagement, investment and partnerships. research and development for pre and clinical research.MRNA Victoria is responsible for establishing a mRNA and RNA industry in Victoria.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |